SG11202112921VA - Multispecific proteins - Google Patents

Multispecific proteins

Info

Publication number
SG11202112921VA
SG11202112921VA SG11202112921VA SG11202112921VA SG11202112921VA SG 11202112921V A SG11202112921V A SG 11202112921VA SG 11202112921V A SG11202112921V A SG 11202112921VA SG 11202112921V A SG11202112921V A SG 11202112921VA SG 11202112921V A SG11202112921V A SG 11202112921VA
Authority
SG
Singapore
Prior art keywords
multispecific proteins
multispecific
proteins
Prior art date
Application number
SG11202112921VA
Inventor
Christian Reichen
Alexander Link
Julia Hepp
Victor Levitsky
Original Assignee
Molecular Partners Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners Ag filed Critical Molecular Partners Ag
Publication of SG11202112921VA publication Critical patent/SG11202112921VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cell Biology (AREA)
SG11202112921VA 2019-06-04 2020-06-03 Multispecific proteins SG11202112921VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962857037P 2019-06-04 2019-06-04
PCT/IB2020/055247 WO2020245746A1 (en) 2019-06-04 2020-06-03 Multispecific proteins

Publications (1)

Publication Number Publication Date
SG11202112921VA true SG11202112921VA (en) 2021-12-30

Family

ID=71069894

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202112921VA SG11202112921VA (en) 2019-06-04 2020-06-03 Multispecific proteins

Country Status (16)

Country Link
US (2) US20200385488A1 (en)
EP (1) EP3980443A1 (en)
JP (1) JP2022535564A (en)
KR (1) KR20220016945A (en)
CN (1) CN114206943A (en)
AR (1) AR119080A1 (en)
AU (1) AU2020289080A1 (en)
BR (1) BR112021024236A2 (en)
CA (1) CA3139051A1 (en)
CO (1) CO2021017845A2 (en)
IL (1) IL288613A (en)
MX (1) MX2021014286A (en)
SG (1) SG11202112921VA (en)
TW (1) TW202112804A (en)
UY (1) UY38739A (en)
WO (1) WO2020245746A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020399230A1 (en) 2019-12-11 2022-06-23 Molecular Partners Ag Recombinant peptide-MHC complex binding proteins and their generation and use
CR20220618A (en) 2020-05-06 2023-01-19 Molecular Partners Ag Novel ankyrin repeat binding proteins and their uses
CN116323672A (en) 2020-08-11 2023-06-23 治纳辅医药科技有限公司 Fusion proteins comprising IL-12 and anti-FAP antibodies and uses thereof
EP3957649A1 (en) * 2020-08-18 2022-02-23 Athebio AG Improved n-terminal capping modules of ankyrin repeat domains
US11981710B2 (en) 2020-08-18 2024-05-14 Athebio Ag N-terminal capping modules of ankyrin repeat domains
MX2023010543A (en) * 2021-03-09 2023-10-13 Molecular Partners Ag Novel darpin based multi-specific t-cell engagers.
WO2022219185A1 (en) * 2021-04-16 2022-10-20 Athebio Ag N-terminal capping modules of ankyrin repeat domains
WO2023121890A1 (en) * 2021-12-23 2023-06-29 Fbd Biologics Limited Cd47/4-1bb-targeting protein complex and methods of use thereof
WO2024028278A1 (en) 2022-08-01 2024-02-08 Molecular Partners Ag Charge modified designed repeat domains and their use
WO2024037743A1 (en) * 2022-08-16 2024-02-22 Athebio Ag Variants of ankyrin repeat domains
WO2023194628A2 (en) * 2022-08-16 2023-10-12 Athebio Ag Variants of ankyrin repeat domains

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
WO2002020565A2 (en) 2000-09-08 2002-03-14 Universität Zürich Collections of repeat proteins comprising repeat modules
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
JP5954990B2 (en) 2008-11-03 2016-07-20 モレキュラー・パートナーズ・アーゲーＭｏｌｅｃｕｌａｒ Ｐａｒｔｎｅｒｓ Ａｇ Binding protein that inhibits VEGF-A receptor interaction
EP2483316A1 (en) 2009-10-02 2012-08-08 Ludwig Institute for Cancer Research Ltd. Anti-fibroblast activation protein antibodies and methods and uses thereof
AR081361A1 (en) 2010-04-30 2012-08-29 Molecular Partners Ag MODIFIED UNION PROTEINS THAT INHIBIT THE RECEPTOR INTERACTION OF THE VASCULAR ENDOTELIAL GROWTH FACTOR FROM GLICOPROTEIN TO VEGF-A
NZ729044A (en) 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
CA2818990C (en) 2010-11-26 2021-06-15 Molecular Partners Ag Designed repeat proteins binding to serum albumin
BR112014032316A2 (en) 2012-06-28 2017-06-27 Molecular Partners Ag engineered ankyrin repeat proteins that bind to platelet-derived growth factor
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
WO2014191574A1 (en) 2013-05-31 2014-12-04 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor
US20170247455A1 (en) 2014-08-22 2017-08-31 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
HUE049982T2 (en) 2014-11-14 2020-11-30 Hoffmann La Roche Antigen binding molecules comprising a tnf family ligand trimer
ES2953482T3 (en) 2015-04-02 2023-11-13 Molecular Partners Ag Ankyrin repeat domains designed with binding specificity for serum albumin
MX2018003820A (en) * 2015-10-02 2018-12-10 F Hoffmann ­La Roche Ag Bispecific antibodies specific for a costimulatory tnf receptor.
JP7074665B2 (en) * 2015-10-07 2022-05-24 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Field of Invention of Tetravalent Bispecific Antibodies to Co-Stimulated TNF Receptors
MX2019003298A (en) 2016-09-22 2019-09-26 Molecular Partners Ag Recombinant binding proteins and their use.

Also Published As

Publication number Publication date
TW202112804A (en) 2021-04-01
KR20220016945A (en) 2022-02-10
CN114206943A (en) 2022-03-18
US20200385488A1 (en) 2020-12-10
IL288613A (en) 2022-02-01
AU2020289080A1 (en) 2021-12-23
AR119080A1 (en) 2021-11-24
JP2022535564A (en) 2022-08-09
CA3139051A1 (en) 2020-12-10
WO2020245746A1 (en) 2020-12-10
UY38739A (en) 2020-12-31
CO2021017845A2 (en) 2022-01-17
MX2021014286A (en) 2022-01-06
BR112021024236A2 (en) 2022-04-26
EP3980443A1 (en) 2022-04-13
US20240190999A1 (en) 2024-06-13

Similar Documents

Publication Publication Date Title
IL288613A (en) Multispecific proteins
IL285366A (en) Multispecific antigen-binding proteins
CA189498S (en) Showerbase
IL292727A (en) Multispecific antibody
IL284664A (en) Multispecific binding proteins
IL280913A (en) Novel methods
DK3737402T3 (en) Modificeret protein
IL289589A (en) Novel methods
IL280912A (en) Novel methods
CA187781S (en) Banquette
GB201907882D0 (en) Methods
IL284317A (en) Pseudofab-based multispecific binding proteins
EP4076343C0 (en) Retinol-based serum
CA189795S (en) Handshower
CA189675S (en) Uroflowmeter
GB201913716D0 (en) Methods
GB201906705D0 (en) Methods
EP3428180A4 (en) Fluorescent protein
CA189047S (en) Hammock-tent
GB201907157D0 (en) Methods
GB201903909D0 (en) Methods
GB201901817D0 (en) Methods
GB201909710D0 (en) Proteins
GB201913320D0 (en) Novel proteins
GB201904756D0 (en) Novel proteins